Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that...
103 insider sale filings on record · latest filing 2026-01-20.
No open-market insider purchases (SEC Form 4 code P) on record for PLRX.